Dys-Immune Therapeutics

Publications

The evidence behind the hypothesis.

Selected publications supporting the scientific rationale of Dys-Immune Therapeutics.

HIV & IFN signaling

Our two studies

Communications Medicine2024

Early elevated IFNα is a key mediator of HIV pathogenesis

H. Le Buanec, V. Schiavon, M. Merandet et al.; including D. Zagury

Associates early elevated IFN-α with HIV pathogenesis, supporting the rationale for modulating this pathway.

View publication
Communications Medicine2024

IFNα induces CCR5 in CD4+ T cells of HIV patients causing pathogenic elevation

H. Le Buanec, V. Schiavon, M. Merandet et al.; including D. Zagury

Describes an IFN-α-driven mechanism in CD4+ T cells of people living with HIV.

View publication

Translational evidence

Type-I interferon modulation in experimental models

Journal of Clinical Investigation2017

Published study of type-I interferon blockade in a humanized mouse model

Cheng L. et al. — full citation and DOI to be confirmed

Humanized mouse model evidence relating to type-I interferon signaling blockade.

Bibliographic details pending
Journal of Clinical Investigation2017

Published study of type-I interferon blockade in a humanized mouse model

Zhen A. et al. — full citation and DOI to be confirmed

Independent humanized mouse work in the same experimental area.

Bibliographic details pending
JCI Insight2022

Anti-IFN-α intervention in SIV-infected rhesus macaques

Swainson L.A. et al. — full citation and DOI to be confirmed

Non-human primate study of anti-IFN-α intervention in SIV infection.

Bibliographic details pending